◎ Sugi Atlas

Atlas / Gene / PSME2

PSME2

gene
On this page

Also known as PA28beta

Summary

PSME2 (proteasome activator subunit 2, HGNC:9569) is a protein-coding gene on chromosome 14q12, encoding Proteasome activator complex subunit 2 (Q9UL46). Implicated in immunoproteasome assembly and required for efficient antigen processing.

The 26S proteasome is a multicatalytic proteinase complex with a highly ordered structure composed of 2 complexes, a 20S core and a 19S regulator. The 20S core is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. The 19S regulator is composed of a base, which contains 6 ATPase subunits and 2 non-ATPase subunits, and a lid, which contains up to 10 non-ATPase subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. The immunoproteasome contains an alternate regulator, referred to as the 11S regulator or PA28, that replaces the 19S regulator. Three subunits (alpha, beta and gamma) of the 11S regulator have been identified. This gene encodes the beta subunit of the 11S regulator, one of the two 11S subunits that is induced by gamma-interferon. Three beta and three alpha subunits combine to form a heterohexameric ring. Six pseudogenes have been identified on chromosomes 4, 5, 8, 10 and 13.

Source: NCBI Gene 5721 — RefSeq curated summary.

At a glance

  • GWAS associations: 1
  • Clinical variants (ClinVar): 48 total
  • Druggable target: yes
  • MANE Select transcript: NM_002818

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:9569
Approved symbolPSME2
Nameproteasome activator subunit 2
Location14q12
Locus typegene with protein product
StatusApproved
AliasesPA28beta
Ensembl geneENSG00000100911
Ensembl biotypeprotein_coding
OMIM602161
Entrez5721

Gene structure

Transcript identifiers

Ensembl transcripts: 31 — 18 protein_coding, 8 retained_intron, 3 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000216802, ENST00000471700, ENST00000558273, ENST00000558931, ENST00000559005, ENST00000559042, ENST00000559056, ENST00000559359, ENST00000559453, ENST00000559493, ENST00000559613, ENST00000560370, ENST00000560410, ENST00000560592, ENST00000560788, ENST00000561103, ENST00000615264, ENST00000630027, ENST00000857133, ENST00000857134, ENST00000857135, ENST00000857136, ENST00000857137, ENST00000857138, ENST00000857139, ENST00000857140, ENST00000857141, ENST00000857142, ENST00000857143, ENST00000931635, ENST00000931636

RefSeq mRNA: 1 — MANE Select: NM_002818 NM_002818

CCDS: CCDS9614

Canonical transcript exons

ENST00000216802 — 11 exons

ExonStartEnd
ENSE000008893612414653424146610
ENSE000034651302414505824145155
ENSE000034985332414537924145465
ENSE000035433902414620824146240
ENSE000035492062414358524143671
ENSE000036035702414571024145772
ENSE000036096542414336524143489
ENSE000036157902414397524144029
ENSE000036313252414440024144468
ENSE000036813022414419224144259
ENSE000037584062414524324145273

Expression profiles

Bgee: expression breadth ubiquitous, 137 present calls, max score 99.36.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 103.1929 / max 846.0559, expressed in 1826 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter IDTPM avgSamples expressed
14253684.39011824
1425377.14391759
1425406.22141471
1425394.06851517
1425340.5592169
2071700.4503230
1425350.3595142

Top tissues by expression

137 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
granulocyteCL:000009499.36gold quality
duodenumUBERON:000211499.29gold quality
vermiform appendixUBERON:000115499.00gold quality
spleenUBERON:000210698.98gold quality
right adrenal glandUBERON:000123398.93gold quality
right adrenal gland cortexUBERON:003582798.93gold quality
mucosa of transverse colonUBERON:000499198.89gold quality
pituitary glandUBERON:000000798.84gold quality
lymph nodeUBERON:000002998.84gold quality
left adrenal glandUBERON:000123498.83gold quality
left adrenal gland cortexUBERON:003582598.81gold quality
adenohypophysisUBERON:000219698.77gold quality
leukocyteCL:000073898.72gold quality
monocyteCL:000057698.69gold quality
adrenal glandUBERON:000236998.67gold quality
rectumUBERON:000105298.65gold quality
right uterine tubeUBERON:000130298.58gold quality
metanephros cortexUBERON:001053398.52gold quality
right lobe of liverUBERON:000111498.48gold quality
small intestine Peyer’s patchUBERON:000345498.46gold quality
small intestineUBERON:000210898.45gold quality
olfactory segment of nasal mucosaUBERON:000538698.35gold quality
liverUBERON:000210798.26gold quality
cortex of kidneyUBERON:000122598.14gold quality
right lobe of thyroid glandUBERON:000111998.13gold quality
tonsilUBERON:000237298.09gold quality
prostate glandUBERON:000236798.04gold quality
smooth muscle tissueUBERON:000113597.99gold quality
left lobe of thyroid glandUBERON:000112097.92gold quality
thyroid glandUBERON:000204697.88gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 2.

ExperimentMarker?Max mean expression
E-MTAB-9801yes7.98
E-MTAB-7606no366.61
E-GEOD-36552no75.32
E-MTAB-6058no74.85
E-ANND-3no0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 10)

  • PA28 selectively up-regulates the presentation of viral MHC class I epitopes and that down regulation PA28 in tumor cells results in impaired presentation of a human TRP2 tumor antigen. (PMID:12200048)
  • Impaired expression of proteasome subunits is involved in the loss of HLA class I expression in human colon cancer cells. (PMID:12519221)
  • knockdown of PA28beta could enhance tumor invasion and metastasis, at least in part, through up-regulation of CLIC1 in gastric adenocarcinoma (PMID:22173998)
  • Naa10p suppresses 28S proteasome activity through interaction with PA28beta. (PMID:23624078)
  • Such a modulation of proteasome activity is explained, at least in part, by the circadian expression of both Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and the proteasome activator PA28ab (PMID:26944190)
  • The functional assays demonstrate that PA28beta inhibited cell growth, proliferation and malignancy of TE-1 cells. Among the differentially expressed proteins, PA28b is a potential tumor inhibitor (PMID:29020885)
  • Conformational maps of human 20S proteasomes reveal PA28- and immuno-dependent inter-ring crosstalks. (PMID:33262340)
  • Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer. (PMID:34257557)
  • Increased expression of PSME2 is associated with clear cell renal cell carcinoma invasion by regulating BNIP3mediated autophagy. (PMID:34779489)
  • PSME2 offers value as a biomarker of M1 macrophage infiltration in pan-cancer and inhibits osteosarcoma malignant phenotypes. (PMID:38385075)

Cross-species orthologs

7 orthologs

OrganismSymbolGene ID
danio_reriopsme2ENSDARG00000033144
mus_musculusPsme2bENSMUSG00000078153
mus_musculusPsme2ENSMUSG00000079197
rattus_norvegicusLOC100362709ENSRNOG00000019246
rattus_norvegicusENSRNOG00000084979
drosophila_melanogasterREGFBGN0029133
caenorhabditis_elegansWBGENE00013435

Paralogs (2): PSME1 (ENSG00000092010), PSME3 (ENSG00000131467)

Protein

Protein identifiers

Proteasome activator complex subunit 2 — Q9UL46 (reviewed: Q9UL46)

Alternative names: 11S regulator complex subunit beta, Activator of multicatalytic protease subunit 2, Proteasome activator 28 subunit beta

All UniProt accessions (7): Q9UL46, A0A087X1Z3, H0YKU2, H0YLD2, H0YLG1, H0YM70, Q86SZ7

UniProt curated annotations — full annotation on UniProt →

Function. Implicated in immunoproteasome assembly and required for efficient antigen processing. The PA28 activator complex enhances the generation of class I binding peptides by altering the cleavage pattern of the proteasome.

Subunit / interactions. Heterodimer of PSME1 and PSME2, which forms a hexameric ring.

Induction. By IFNG/IFN-gamma.

Similarity. Belongs to the PA28 family.

RefSeq proteins (1): NP_002809* (*=MANE)

Domains & families (InterPro)

IDNameType
IPR003185Proteasome_activ_PA28_NDomain
IPR003186PA28_CDomain
IPR009077Proteasome_activ_PA28Family
IPR036252Proteasome_activ_sfHomologous_superfamily
IPR036996PA28_N_sfHomologous_superfamily
IPR036997PA28_C_sfHomologous_superfamily

Pfam: PF02251, PF02252

UniProt features (16 total): helix 7, turn 2, modified residue 2, initiator methionine 1, chain 1, strand 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

5 structures.

PDBMethodResolution (Å)
7NAOELECTRON MICROSCOPY2.9
8CXBELECTRON MICROSCOPY2.9
7NAPELECTRON MICROSCOPY3.2
7DR6ELECTRON MICROSCOPY4.1
7DRWELECTRON MICROSCOPY4.2

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-Q9UL46-F191.720.84

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 2, 10

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

IDPathway
R-HSA-1236974ER-Phagosome pathway
R-HSA-1236978Cross-presentation of soluble exogenous antigens (endosomes)
R-HSA-8950505Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
R-HSA-9907900Proteasome assembly
R-HSA-9912633Antigen processing: Ub, ATP-independent proteasomal degradation

MSigDB gene sets: 370 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_UP, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, KEGG_PROTEASOME, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_RESPONSE_TO_TYPE_I_INTERFERON, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, WIELAND_UP_BY_HBV_INFECTION, chr14q12, PUJANA_CHEK2_PCC_NETWORK, CAIRO_HEPATOBLASTOMA_CLASSES_DN

GO Biological Process (2): regulation of proteasomal protein catabolic process (GO:0061136), regulation of G1/S transition of mitotic cell cycle (GO:2000045)

GO Molecular Function (3): identical protein binding (GO:0042802), endopeptidase activator activity (GO:0061133), protein binding (GO:0005515)

GO Cellular Component (7): proteasome complex (GO:0000502), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), proteasome activator complex (GO:0008537), membrane (GO:0016020), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-4 pathways:

CategoryPathways
Antigen processing-Cross presentation2
Interleukin-12 signaling1
Post-translational protein modification1
Class I MHC mediated antigen processing & presentation1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
cellular anatomical structure4
proteasomal protein catabolic process1
regulation of protein catabolic process1
G1/S transition of mitotic cell cycle1
regulation of mitotic cell cycle phase transition1
regulation of cell cycle G1/S phase transition1
protein binding1
endopeptidase activity1
peptidase activator activity1
endopeptidase regulator activity1
binding1
intracellular protein-containing complex1
endopeptidase complex1
nuclear lumen1
intracellular anatomical structure1
cytoplasm1
proteasome accessory complex1
protein-containing complex1
extracellular vesicle1

Protein interactions and networks

STRING

1636 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
PSME2PSME1Q06323984
PSME2PSMB8P28062933
PSME2PSMB10P40306925
PSME2PSMB9P28065844
PSME2PSMB5P28074843
PSME2PSMB7Q99436703
PSME2IRF9Q00978636
PSME2PSME4Q14997631
PSME2PSMB4P28070620
PSME2IRF1P10914586
PSME2PSMD7P51665572
PSME2IFNGP01579559
PSME2IFI35P80217553
PSME2CANXP27824546
PSME2NAA10P41227522

IntAct

148 interactions, top by confidence:

ABTypeScore
PSMA1PSMA7psi-mi:“MI:2364”(proximity)0.950
PSMA1PSMA7psi-mi:“MI:0915”(physical association)0.950
PSMA1PSMA7psi-mi:“MI:0914”(association)0.950
FBXO7SKP1psi-mi:“MI:0914”(association)0.900
PSME1PSME2psi-mi:“MI:0915”(physical association)0.850
PSMA2PSMA7psi-mi:“MI:0914”(association)0.850
PSMA5PSMA7psi-mi:“MI:0914”(association)0.800
PSMB7PSMA7psi-mi:“MI:0914”(association)0.790
PSMB2PSMA7psi-mi:“MI:0914”(association)0.790
PSMB3PSMA7psi-mi:“MI:0914”(association)0.770
SDCBPPSME2psi-mi:“MI:0915”(physical association)0.740
PSMB2PSMD11psi-mi:“MI:0914”(association)0.730
PSMB4PSMA7psi-mi:“MI:0914”(association)0.730
PSME2PSME2psi-mi:“MI:0915”(physical association)0.720
CFTRESYT2psi-mi:“MI:0914”(association)0.710

BioGRID (246): PSME2 (Affinity Capture-MS), PSME2 (Affinity Capture-MS), PSME2 (Affinity Capture-MS), PSME2 (Affinity Capture-MS), PSME2 (Affinity Capture-MS), PSME2 (Two-hybrid), PSME2 (Two-hybrid), PSME2 (Affinity Capture-MS), PSME2 (Affinity Capture-MS), PSME2 (Affinity Capture-MS), PSME2 (Affinity Capture-MS), PSME2 (Affinity Capture-MS), PSME2 (Affinity Capture-MS), PSME2 (Affinity Capture-MS), PSME2 (Affinity Capture-MS)

ESM2 similar proteins: A0A223HDI2, A2BG43, B0BLT4, B0BNM9, B0YN54, O64587, O74432, P68265, P68266, P97371, P97372, Q06323, Q0VCQ0, Q19555, Q29RK9, Q4U5R3, Q54QV0, Q58D63, Q5E9G3, Q5F495, Q5HZ92, Q5R5Z0, Q5RDB1, Q5TA50, Q5XIS2, Q63797, Q63798, Q63ZQ3, Q64L94, Q66JG2, Q6DBQ8, Q6NLQ3, Q6NU44, Q6PEB6, Q7K0E3, Q7XVN7, Q863Z0, Q86TA1, Q8BS40, Q8L7U7

Diamond homologs: P58238, P61289, P61290, P61291, P97371, P97372, Q06323, Q4R4V3, Q4U5R3, Q5E9G3, Q5F3J5, Q5RFD3, Q63797, Q63798, Q64L94, Q863Z0, Q967U1, Q9UL46

SIGNOR signaling

1 interactions.

AEffectBMechanism
PSME2“up-regulates activity”“26S Proteasome”binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 106 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

PathwayPartnersFoldFDR
Antigen processing: Ub, ATP-independent proteasomal degradation12100.8×1e-21
Cross-presentation of soluble exogenous antigens (endosomes)1867.2×3e-27
Proteasome assembly2163.0×3e-31
Vpu mediated degradation of CD41662.5×1e-23
Regulation of activated PAK-2p34 by proteasome mediated degradation1561.4×1e-22
Regulation of ornithine decarboxylase (ODC)1560.0×2e-22
Autodegradation of the E3 ubiquitin ligase COP11558.6×2e-22
Ubiquitin-dependent degradation of Cyclin D1558.6×2e-22

GO biological processes:

GO termPartnersFoldFDR
proteasome-mediated ubiquitin-dependent protein catabolic process2113.0×3e-15

Disease & clinical

Clinical variants and AI predictions

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance24
Likely benign1
Benign2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1454 predictions. Top by Δscore:

VariantEffectΔscore
14:24143583:A:ACdonor_gain1.0000
14:24143584:C:CCdonor_gain1.0000
14:24143973:A:ACdonor_gain1.0000
14:24143974:C:CCdonor_gain1.0000
14:24143974:CTA:Cdonor_gain1.0000
14:24144111:T:TAdonor_gain1.0000
14:24144157:A:ACdonor_gain1.0000
14:24144157:ACTGC:Adonor_gain1.0000
14:24144158:C:CCdonor_gain1.0000
14:24144158:CTGCC:Cdonor_gain1.0000
14:24144161:C:Adonor_gain1.0000
14:24144190:A:ACdonor_gain1.0000
14:24144191:C:CCdonor_gain1.0000
14:24144395:CTTA:Cdonor_loss1.0000
14:24144396:TTACC:Tdonor_loss1.0000
14:24144398:AC:Adonor_loss1.0000
14:24144399:CC:Cdonor_loss1.0000
14:24144465:TCAC:Tacceptor_gain1.0000
14:24144466:CAC:Cacceptor_gain1.0000
14:24144466:CACC:Cacceptor_gain1.0000
14:24144467:AC:Aacceptor_gain1.0000
14:24144467:ACCTG:Aacceptor_loss1.0000
14:24144468:CCTG:Cacceptor_gain1.0000
14:24144469:C:CCacceptor_gain1.0000
14:24144471:G:Cacceptor_gain1.0000
14:24144471:G:GCacceptor_gain1.0000
14:24144474:T:TCacceptor_gain1.0000
14:24145156:C:CCacceptor_gain1.0000
14:24145272:ATC:Aacceptor_loss1.0000
14:24145785:T:TCacceptor_gain1.0000

AlphaMissense

1576 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
14:24144415:A:CF138L1.000
14:24144415:A:TF138L1.000
14:24144417:A:GF138L1.000
14:24144400:C:AQ143H0.999
14:24144400:C:GQ143H0.999
14:24144413:C:TG139E0.999
14:24144425:C:AG135V0.999
14:24144425:C:TG135E0.999
14:24143641:C:GD195H0.998
14:24143994:G:TA178D0.998
14:24144012:C:TG172E0.998
14:24144013:C:AG172W0.998
14:24144016:G:TR171S0.998
14:24144416:A:CF138C0.998
14:24144416:A:GF138S0.998
14:24144421:A:CN136K0.998
14:24144421:A:TN136K0.998
14:24144459:A:GW124R0.998
14:24144459:A:TW124R0.998
14:24143436:C:AK231N0.997
14:24143436:C:GK231N0.997
14:24143640:T:AD195V0.997
14:24143640:T:GD195A0.997
14:24144012:C:AG172V0.997
14:24144413:C:AG139V0.997
14:24144414:C:GG139R0.997
14:24144414:C:TG139R0.997
14:24144425:C:GG135A0.997
14:24144428:T:AD134V0.997
14:24144429:C:GD134H0.997

dbSNP variants (sampled 300 via entrez): RS1000727801 (14:24146254 A>G), RS1000829856 (14:24143826 T>C,G), RS1000965185 (14:24143489 C>T), RS1001574712 (14:24147343 G>A,C,T), RS1001833316 (14:24145798 G>A), RS1005211698 (14:24145343 G>A), RS1005681520 (14:24147002 C>A,G), RS1006150969 (14:24144951 T>C), RS1006231674 (14:24146779 T>G), RS1006768202 (14:24147885 G>A), RS1008964545 (14:24147527 G>A,C,T), RS1008992280 (14:24147315 G>A), RS1009299025 (14:24145885 G>T), RS1009743112 (14:24146212 T>C), RS1010383176 (14:24148291 A>G)

Disease associations

OMIM: gene MIM:602161 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

StudyTraitp-value
GCST002969_3Suicide behavior8.000000e-06

EFO canonical traits (1, from GWAS)

EFO IDTrait name
EFO:0007623suicide behaviour

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295982 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChemblTypeValueUnitMolecule
5.97Kd1063nMCHEMBL3752910
5.97ED501063nMCHEMBL3752910
5.01Kd9774nMCHEMBL5653589
5.01ED509774nMCHEMBL5653589

PubChem BioAssay actives

2 with measured affinity, of 12 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

CompoundAssayTypeValueUnit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide2149134: Binding affinity to human PSME2 incubated for 45 mins by Kinobead based pull down assaykd1.0635uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide2149134: Binding affinity to human PSME2 incubated for 45 mins by Kinobead based pull down assaykd9.7737uM

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

ChemicalActions (top 5)PubMed papers
Hydrogen Peroxideaffects expression, increases expression2
Nickelincreases expression2
Rotenonedecreases expression2
Tretinoinincreases expression2
aristolochic acid Iincreases expression1
FR900359decreases phosphorylation1
bisphenol Aincreases expression1
pyrogallol 1,3-dimethyl etheraffects cotreatment, decreases expression, affects localization, increases expression1
sodium arseniteincreases expression1
cobaltous chloridedecreases expression1
ochratoxin Adecreases expression1
tamibaroteneincreases expression1
benzyloxycarbonylleucyl-leucyl-leucine aldehydedecreases expression1
CGP 52608affects binding, increases reaction1
perfluoro-n-nonanoic acidincreases expression1
deguelindecreases expression1
K 7174decreases expression1
erucylphospho-N,N,N-trimethylpropylammoniumdecreases expression1
ICG 001increases expression1
jinfukangaffects cotreatment, increases expression1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-olincreases expression1
bisphenol AFincreases expression1
Arsenic Trioxideincreases expression1
Acetaminophenincreases expression1
Cisplatinincreases expression, affects cotreatment1
Coumestrolincreases expression1
Diurondecreases expression1
Doxorubicindecreases expression1
Dustdecreases expression1
Enzyme Inhibitorsdecreases activity, increases O-linked glycosylation1

ChEMBL screening assays

9 unique, capped per target: 9 binding

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL4118687BindingBinding affinity to PSME2 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assayStudies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 78

This page pulls from 78 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot